Literature DB >> 35199836

Relating Glutamate, Conditioned, and Clinical Hallucinations via 1H-MR Spectroscopy.

Pantelis Leptourgos1, Sonia Bansal2, Jenna Dutterer2, Adam Culbreth2, Albert Powers1, Praveen Suthaharan1, Joshua Kenney1, Molly Erickson3, James Waltz2, S Andrea Wijtenburg2, Frank Gaston2, Laura M Rowland2, James Gold2, Philip Corlett1.   

Abstract

BACKGROUND AND HYPOTHESIS: Hallucinations may be driven by an excessive influence of prior expectations on current experience. Initial work has supported that contention and implicated the anterior insula in the weighting of prior beliefs. STUDY
DESIGN: Here we induce hallucinated tones by associating tones with the presentation of a visual cue. We find that people with schizophrenia who hear voices are more prone to the effect and using computational modeling we show they overweight their prior beliefs. In the same participants, we also measured glutamate levels in anterior insula, anterior cingulate, dorsolateral prefrontal, and auditory cortices, using magnetic resonance spectroscopy. STUDY
RESULTS: We found a negative relationship between prior-overweighting and glutamate levels in the insula that was not present for any of the other voxels or parameters.
CONCLUSIONS: Through computational psychiatry, we bridge a pathophysiological theory of psychosis (glutamate hypofunction) with a cognitive model of hallucinations (prior-overweighting) with implications for the development of new treatments for hallucinations.
© The Author(s) 2022. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  MR spectroscopy (MRS); computational psychiatry; conditioned hallucinations; predictive processing; schizophrenia

Mesh:

Substances:

Year:  2022        PMID: 35199836      PMCID: PMC9212089          DOI: 10.1093/schbul/sbac006

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   7.348


  40 in total

Review 1.  Glutamatergic model psychoses: prediction error, learning, and inference.

Authors:  Philip R Corlett; Garry D Honey; John H Krystal; Paul C Fletcher
Journal:  Neuropsychopharmacology       Date:  2010-09-22       Impact factor: 7.853

Review 2.  A theory of cortical responses.

Authors:  Karl Friston
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-04-29       Impact factor: 6.237

Review 3.  Glutamate in schizophrenia: a focused review and meta-analysis of ¹H-MRS studies.

Authors:  Anouk Marsman; Martijn P van den Heuvel; Dennis W J Klomp; René S Kahn; Peter R Luijten; Hilleke E Hulshoff Pol
Journal:  Schizophr Bull       Date:  2011-07-11       Impact factor: 9.306

4.  NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia.

Authors:  Alan Anticevic; Mark Gancsos; John D Murray; Grega Repovs; Naomi R Driesen; Debra J Ennis; Mark J Niciu; Peter T Morgan; Toral S Surti; Michael H Bloch; Ramachandran Ramani; Mark A Smith; Xiao-Jing Wang; John H Krystal; Philip R Corlett
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-25       Impact factor: 11.205

5.  Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.

Authors:  B Moghaddam; B Adams; A Verma; D Daly
Journal:  J Neurosci       Date:  1997-04-15       Impact factor: 6.167

6.  Pavlovian conditioning-induced hallucinations result from overweighting of perceptual priors.

Authors:  A R Powers; C Mathys; P R Corlett
Journal:  Science       Date:  2017-08-11       Impact factor: 47.728

7.  Glutamate as a mediating transmitter for auditory hallucinations in schizophrenia: a (1)H MRS study.

Authors:  Kenneth Hugdahl; Alexander R Craven; Merethe Nygård; Else-Marie Løberg; Jan Øystein Berle; Erik Johnsen; Rune Kroken; Karsten Specht; Ole A Andreassen; Lars Ersland
Journal:  Schizophr Res       Date:  2014-12-24       Impact factor: 4.939

Review 8.  Are Hallucinations Due to an Imbalance Between Excitatory and Inhibitory Influences on the Brain?

Authors:  Renaud Jardri; Kenneth Hugdahl; Matthew Hughes; Jérôme Brunelin; Flavie Waters; Ben Alderson-Day; Dave Smailes; Philipp Sterzer; Philip R Corlett; Pantelis Leptourgos; Martin Debbané; Arnaud Cachia; Sophie Denève
Journal:  Schizophr Bull       Date:  2016-06-03       Impact factor: 9.306

9.  Computational psychiatry: a Rosetta Stone linking the brain to mental illness.

Authors:  Philip R Corlett; Paul C Fletcher
Journal:  Lancet Psychiatry       Date:  2014-08-12       Impact factor: 27.083

10.  Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level: A Mega-analysis of Individual Participant-Level Data.

Authors:  Kate Merritt; Philip K McGuire; Alice Egerton; André Aleman; Wolfgang Block; Oswald J N Bloemen; Faith Borgan; Juan R Bustillo; Aristides A Capizzano; Jennifer Marie Coughlin; Camilo De la Fuente-Sandoval; Arsime Demjaha; Kara Dempster; Kim Q Do; Fei Du; Peter Falkai; Beata Galinska-Skok; Jurgen Gallinat; Charles Gasparovic; Cedric E Ginestet; Naoki Goto; Ariel Graff-Guerrero; Beng Choon Ho; Oliver D Howes; Sameer Jauhar; Peter Jeon; Tadafumi Kato; Charles A Kaufmann; Lawrence S Kegeles; Matcheri Keshavan; Sang-Young Kim; Hiroshi Kunugi; John Lauriello; Edith Jantine Liemburg; Meghan E Mcilwain; Gemma Modinos; Elias D Mouchlianitis; Jun Nakamura; Igor Nenadic; Dost Öngür; Miho Ota; Lena Palaniyappan; Christos Pantelis; Eric Plitman; Sotirios Posporelis; Scot E Purdon; Jürgen R Reichenbach; Perry F Renshaw; Bruce R Russell; Akira Sawa; Martin Schaefer; Dikoma C Shungu; Stefan Smesny; Jeffrey A Stanley; James M Stone; Agata Szulc; Reggie Taylor; Katy Thakkar; Jean Théberge; Philip G Tibbo; Therese van Amelsvoort; Jerzy Walecki; Peter C Williamson; Stephen James Wood; Lijing Xin; Hidenori Yamasue
Journal:  JAMA Psychiatry       Date:  2021-06-01       Impact factor: 21.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.